Family Medicine

A review in JAMA describes idiopathic normal pressure hydrocephalus (iNPH) as a progressive disorder affecting an estimated 1% to 4% of adults 65 and older, and 6% to 8% of those over 80, involving cerebrospinal fluid circulation, vascular dysfunction, and white matter injury. The review reports that gait disturbance occurs in 85% to 95% of patients, urinary dysfunction in 75% to 90%, and cognitive impairment in 60% to 80%, with diagnosis relying on clinical findings, MRI showing ventricular enlargement, and large-volume or extended lumbar puncture to predict shunt responsiveness. It states that after shunt placement, approximately 75% to 80% of patients show gait improvement, 50% to 70% show cognitive or urinary improvement, and complications such as overdrainage/underdrainage (10%-30%), shunt malfunction (10%-20%), and infection (under 1% to 2%) can occur.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.

A difference-in-differences analysis using Epic Cosmos data examined over 1.6 million US deliveries from 2013 to 2024, comparing unscheduled cesarean births to vaginal births before and after 2016 publication of trial evidence supporting adjunctive azithromycin at cesarean delivery. The study reported that azithromycin use during cesarean births rose from 2.2% before 2016 to 39.6% after, a 37.6 percentage point adjusted difference-in-differences increase relative to vaginal births, while postpartum infection after cesarean fell from 9.2% to 8.0%, a 2.0 percentage point adjusted decrease. The authors concluded that after the trial evidence was published, azithromycin use for unscheduled cesarean delivery increased and postpartum infection rates decreased in the US.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.

Baxter Healthcare Corporation has issued a Class II recall for Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg/mL), supplied in 50 mL single-dose GALAXY Containers under NDC 0338-9549-50. The recall notice cites current Good Manufacturing Practice (CGMP) deviations as the reason for the action. No further clinical or patient-impact details were provided in the source material.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.

Baxter Healthcare Corporation has issued a Class II recall of Vancomycin Injection, USP in 5% Dextrose, 1 g per 200mL (5 mg/mL), supplied in GALAXY Single-Dose Containers, NDC 0338-3552-48. The recall notice cites current good manufacturing practice (CGMP) deviations as the reason for the action. The affected product is an Rx-only, sterile, nonpyrogenic, iso-osmotic solution manufactured by Baxter Healthcare Corporation of Deerfield, IL.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.

Baxter Healthcare Corporation has issued a Class II recall for Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 mg/mL), supplied in GALAXY 50 mL Single Dose Containers (NDC 43066-995-24). The FDA-classified recall notice cites current Good Manufacturing Practice (CGMP) deviations as the reason for the action. No further clinical detail on the specific deviation was provided in the source notice.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.